Lamivudine/Zidovudine Teva

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

lamivudine, zidovudine

Available from:

Teva Pharma B.V. 

ATC code:

J05AR01

INN (International Name):

lamivudine, zidovudine

Therapeutic group:

Antivirusi za sistemsko uporabo

Therapeutic area:

Okužbe z virusom HIV

Therapeutic indications:

Zdravilo Lamivudin / Zidovudin Teva je indicirano za protiretrovirusno kombinirano terapijo za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV).

Product summary:

Revision: 16

Authorization status:

Umaknjeno

Authorization date:

2011-02-28

Patient Information leaflet

                                26
TEVA B.V.
Swensweg 5
20314GA Haarlem
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/10/663/001
EU/1/10/663/002
13.
ŠTEVILKA SERIJE
Lot:
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Lamivudin/zidovudin Teva
17.
EDINSTVENA OZNAKA
– DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA
– V BERLJIVI OBLIKI_ _
PC
SN
NN
Zdravilo nima več dovoljenja za promet
27
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
FOLIJA PRETISNEGA OMOTA
1.
IME ZDRAVILA
Lamivudin/zidovudin Teva 150 mg/300 mg filmsko obložene tablete
lamivudin/zidovudin
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V.
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP:
4.
ŠTEVILKA SERIJE
Lot:
5.
DRUGI PODATKI
Zdravilo nima več dovoljenja za promet
28
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA ZA PLASTENKO
1.
IME ZDRAVILA
Lamivudin/zidovudin Teva 150 mg/300 mg filmsko obložene tablete
lamivudin/zidovudin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje
lamivudin 150 mg
zidovudin 300 mg
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
60 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP:
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Zdravilo nima več dovoljenja za promet
29
TEVA B.V.
Swensweg 5
2031GA Haarlem
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/10/663/001
EU/1/10/663/002
13.
ŠTEVILKA SERIJE
Lot:
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima več dovoljenja za promet
2
1.
IME ZDRAVILA
Lamivudin/zidovudin Teva 150 mg/300 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 150 mg lamivudina in 300 mg
zidovudina.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Bele, bikonveksne filmsko obložene tablete v obliki kapsule z zarezo
in oznako "L/Z", odtisnjeno na
eni ter »150/300« na drugi strani.
Tableta se lahko deli na enaka odmerka.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Lamivudin/zidovudin Teva je indicirano za kombinirano
protiretrovirusno zdravljenje okužb
z virusom humane imunske pomanjkljivosti (HIV) (glejte poglavje 4.2).
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje mora uvesti zdravnik z izkušnjami pri zdravljenju okužb
z virusom HIV.
Bolnik lahko zdravilo Lamivudin/zidovudin Teva jemlje skupaj s hrano
ali brez nje.
Najbolje je, da bolnik tableto (tablete) pogoltne celo (cele) brez
drobljenja, saj le v tem primeru
povsem zanesljivo vzame celoten predpisani odmerek. Bolnik, ki tablet
ne more pogoltniti, lahko
tablete zdrobi in jih doda v manjšo količino redke hrane ali
tekočine, ki jo mora nato v celoti takoj
zaužiti (glejte poglavje 5.2).
Odrasli in mladostniki s telesno maso 30 kg ali več
_ _
_ _
Priporočeni odmerek zdravila Lamivudin/zidovudin Teva je ena tableta
dvakrat na dan.
Otroci s telesno maso od 21 kg do 30 kg
Priporočeni peroralni odmerek zdravila Lamivudin/zidovudin Teva je
polovica tablete zjutraj in ena
cela tableta zvečer.
Otroci s telesno maso od 14 kg do 21 kg
Priporočeni peroralni odmerek zdravila Lamivudin/zidovudin Teva je
polovica tablete dvakrat na dan.
Režim odmerjanja pri otrocih s telesno maso od 14 do 30 kg temelji
predvsem na podatkih
farmakokinetičnega modeliranja, na voljo pa so tudi podatki iz
kliničnih študij s posamezno
komponento zdravila, lamivudinom in zidovudinom. Zaradi možne
prekomerne farmakokinetične
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-03-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-03-2023
Public Assessment Report Public Assessment Report Bulgarian 21-03-2023
Patient Information leaflet Patient Information leaflet Spanish 21-03-2023
Public Assessment Report Public Assessment Report Spanish 21-03-2023
Patient Information leaflet Patient Information leaflet Czech 21-03-2023
Public Assessment Report Public Assessment Report Czech 21-03-2023
Patient Information leaflet Patient Information leaflet Danish 21-03-2023
Public Assessment Report Public Assessment Report Danish 21-03-2023
Patient Information leaflet Patient Information leaflet German 21-03-2023
Public Assessment Report Public Assessment Report German 21-03-2023
Patient Information leaflet Patient Information leaflet Estonian 21-03-2023
Public Assessment Report Public Assessment Report Estonian 21-03-2023
Patient Information leaflet Patient Information leaflet Greek 21-03-2023
Public Assessment Report Public Assessment Report Greek 21-03-2023
Patient Information leaflet Patient Information leaflet English 21-03-2023
Public Assessment Report Public Assessment Report English 21-03-2023
Patient Information leaflet Patient Information leaflet French 21-03-2023
Public Assessment Report Public Assessment Report French 21-03-2023
Patient Information leaflet Patient Information leaflet Italian 21-03-2023
Public Assessment Report Public Assessment Report Italian 21-03-2023
Patient Information leaflet Patient Information leaflet Latvian 21-03-2023
Public Assessment Report Public Assessment Report Latvian 21-03-2023
Patient Information leaflet Patient Information leaflet Lithuanian 21-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-03-2023
Public Assessment Report Public Assessment Report Lithuanian 21-03-2023
Patient Information leaflet Patient Information leaflet Hungarian 21-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 21-03-2023
Public Assessment Report Public Assessment Report Hungarian 21-03-2023
Patient Information leaflet Patient Information leaflet Maltese 21-03-2023
Public Assessment Report Public Assessment Report Maltese 21-03-2023
Patient Information leaflet Patient Information leaflet Dutch 21-03-2023
Public Assessment Report Public Assessment Report Dutch 21-03-2023
Patient Information leaflet Patient Information leaflet Polish 21-03-2023
Public Assessment Report Public Assessment Report Polish 21-03-2023
Patient Information leaflet Patient Information leaflet Portuguese 21-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 21-03-2023
Public Assessment Report Public Assessment Report Portuguese 21-03-2023
Patient Information leaflet Patient Information leaflet Romanian 21-03-2023
Public Assessment Report Public Assessment Report Romanian 21-03-2023
Patient Information leaflet Patient Information leaflet Slovak 21-03-2023
Public Assessment Report Public Assessment Report Slovak 21-03-2023
Patient Information leaflet Patient Information leaflet Finnish 21-03-2023
Public Assessment Report Public Assessment Report Finnish 21-03-2023
Patient Information leaflet Patient Information leaflet Swedish 21-03-2023
Public Assessment Report Public Assessment Report Swedish 21-03-2023
Patient Information leaflet Patient Information leaflet Norwegian 21-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 21-03-2023
Patient Information leaflet Patient Information leaflet Icelandic 21-03-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 21-03-2023
Patient Information leaflet Patient Information leaflet Croatian 21-03-2023
Public Assessment Report Public Assessment Report Croatian 21-03-2023

Search alerts related to this product